1. Home
  2. ZCMD vs ABP Comparison

ZCMD vs ABP Comparison

Compare ZCMD & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

HOLD

Current Price

$0.52

Market Cap

18.5M

Sector

Real Estate

ML Signal

HOLD

ABP

Abpro Holdings Inc

HOLD

Current Price

$4.77

Market Cap

15.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZCMD
ABP
Founded
2012
2004
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.5M
15.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ZCMD
ABP
Price
$0.52
$4.77
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
14.6K
18.1K
Earning Date
12-24-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,117,523.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
50.00
52 Week Low
$0.46
$4.51
52 Week High
$2.28
$153.90

Technical Indicators

Market Signals
Indicator
ZCMD
ABP
Relative Strength Index (RSI) 31.75 40.32
Support Level $0.46 $4.55
Resistance Level $0.63 $5.08
Average True Range (ATR) 0.06 0.40
MACD -0.00 -0.23
Stochastic Oscillator 23.53 4.81

Price Performance

Historical Comparison
ZCMD
ABP

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company incorporated in the Cayman Islands. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provide the healthcare information, education, and training services to the healthcare professionals under their MDMOOC brand. It also provide focused patient management services, through Zhongxun IT system and WeChat mini program and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About ABP Abpro Holdings Inc

Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.

Share on Social Networks: